Remove Clinical Development Remove Drug Research Remove Trials
article thumbnail

Why Proactive AME Studies are Critical to Accelerating Your Approval Journey

Conversations in Drug Development Trends

During clinical development, new chemical entities (NCEs) require an absorption, metabolism, and excretion (AME) study. The post Why Proactive AME Studies are Critical to Accelerating Your Approval Journey appeared first on Worldwide Clinical Trials.

article thumbnail

Pediatric Development Plans: Key Considerations

Cytel

Historically, many drugs have been prescribed to children even though this patient population have largely been excluded from clinical trials. There is an obvious logic.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Innovation Drives Excellence, Innovent Successfully Held 2020 Virtual R&D Day

The Pharma Data

Growing into a biopharmaceutical company, Innovent has built an integrated platform covering from drug discovery, CMC, clinical development and commercialization. that are fast progressing clinical trials. Michael Yu reviewed the history and achievements in the past nine years since the establishment of Innovent.

article thumbnail

Bayer, Broad Institute Extend Cardiovascular Drug Research Pact

The Pharma Data

The Broad Institute, one of the world’s leading biomedical research centers, brings deep capabilities in genomics, systems biology, and computational analytics. Bayer contributes decades of experience in pharmaceutical R&D, encompassing drug design, medicinal chemistry, and clinical development for both small molecules and biologics.

article thumbnail

Using clinical genomics and AI in drug development to elevate success

Drug Target Review

These hurdles not only delay patient access to innovative treatments but also threaten the economic sustainability of research and development (R&D) and the advancement of medical innovation. The financial burden of drug development is substantial, often exceeding $2 billion per drug.